Form 4: Silence Therapeutics Director Sells Shares in Recent Transactions

Director Richard Ian Griffiths of Silence Therapeutics plc reports selling American Depositary Shares (ADS) on May 13 and 14, 2025.

Summary

• Richard Ian Griffiths, a director of Silence Therapeutics plc, filed a Form 4 detailing changes in beneficial ownership.
• On May 13, 2025, Griffiths sold 94,234 American Depositary Shares (ADS) at a price of $4.01.
• On May 14, 2025, Griffiths sold 55,766 ADS at a price of $4.07.
• Each ADS is immediately convertible into three ordinary shares.
• Following these transactions, Griffiths directly owns 11,120,853 ordinary shares.
• The transactions were purchases, indicated by the code 'P'.

Sentiment

Score: 4

Explanation: Director share sales can create negative sentiment, but without additional context, it's difficult to assess the full impact. The sales were relatively small compared to the total holdings.

Negatives

• A director selling shares could be perceived negatively by investors.

Risks

• Director share sales could indicate a lack of confidence in the company's future performance, potentially impacting investor sentiment.

Industry Context

Form 4 filings are routine disclosures, but the market often scrutinizes insider transactions for signals about a company's prospects. Director sales can sometimes raise concerns, especially if they are substantial or occur frequently.

Comparison to Industry Standards

• Comparing these transactions to similar insider sales at comparable biotech companies would provide context.
• For example, reviewing Form 4 filings of directors at Alnylam Pharmaceuticals or Arrowhead Pharmaceuticals could offer insights into typical insider trading patterns in the RNAi therapeutics space.
• Analyzing the size of the transactions relative to Griffiths' total holdings and the company's market capitalization is also important.

Stakeholder Impact

• Shareholders may react to the director's share sales, potentially leading to price fluctuations.
• Employees may be concerned if they perceive the sales as a lack of confidence in the company's future.

Key Dates

Keywords

Silence Therapeutics, Richard Ian Griffiths, Form 4, ADS, American Depositary Shares, Beneficial Ownership, Director, Share Sale